137 related articles for article (PubMed ID: 2788601)
1. Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.
Sweet F; Rosik LO; Sommers GM; Collins JL
Gynecol Oncol; 1989 Sep; 34(3):305-11. PubMed ID: 2788601
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancers specifically bind daunorubicin-OC-125 conjugate: an immunofluorescence study.
Dezsö B; Török I; Rosik LO; Sweet F
Gynecol Oncol; 1990 Oct; 39(1):60-4. PubMed ID: 2227573
[TBL] [Abstract][Full Text] [Related]
3. Electrophilic analogues of daunorubicin and doxorubicin.
Rosik LO; Sweet F
Bioconjug Chem; 1990; 1(4):251-6. PubMed ID: 2096917
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Biddle WC; Haruta Y; Seon BK; Henderson ES; Sarcione EJ
Leuk Res; 1989; 13(8):699-707. PubMed ID: 2529399
[TBL] [Abstract][Full Text] [Related]
5. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
[TBL] [Abstract][Full Text] [Related]
6. Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer.
Haisma HJ; Battaile A; Stradtman EW; Knapp RC; Zurawski VR
Int J Cancer; 1987 Dec; 40(6):758-62. PubMed ID: 3480271
[TBL] [Abstract][Full Text] [Related]
7. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells.
Matsuoka Y; Nakashima T; Endo K; Yoshida T; Kunimatsu M; Sakahara H; Koizumi M; Nakagawa T; Yamaguchi N; Torizuka K
Cancer Res; 1987 Dec; 47(23):6335-40. PubMed ID: 3315184
[TBL] [Abstract][Full Text] [Related]
8. Construction of an immunoradiometric assay for ovarian cancer associated antigen CA125 recognizing different antigenic determinant.
Saga T; Endo K; Nakashima T; Awaji T; Koizumi M; Kawamura Y; Watanabe Y; Konishi J; Nonogaki H; Nanbu Y
Acta Obstet Gynecol Scand; 1990; 69(2):175-81. PubMed ID: 1696770
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotypic network.
Schultes BC; Reinsberg J; Schlebusch H; Oehr P; Biersack HJ; Krebs D; Wagner U
Eur J Clin Chem Clin Biochem; 1993 Jul; 31(7):427-32. PubMed ID: 8399782
[TBL] [Abstract][Full Text] [Related]
10. [Basic study for immunoscintigraphy of ovarian cancer using 99mTc labeled F(ab')2 fragments of monoclonal antibody].
Sugiyama S
Kaku Igaku; 1994 Apr; 31(4):327-36. PubMed ID: 8196229
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.
Chang K; Pastan I; Willingham MC
Int J Cancer; 1992 Feb; 50(3):373-81. PubMed ID: 1735605
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of immunoconjugates between cisplatin and an anti-CA125 monoclonal antibody on ovarian cancer cell lines.
Beck E; Hofmann M; Bernhardt G; Jäger W; Wildt L; Lang N
Cell Biophys; 1994; 24-25():163-73. PubMed ID: 7736521
[TBL] [Abstract][Full Text] [Related]
14. [Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian cancer cell lines].
Murakami F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Feb; 48(2):125-32. PubMed ID: 8718548
[TBL] [Abstract][Full Text] [Related]
15. [A new monoclonal antibody (SH-9) recognizes the low molecular mass of ovarian cancer antigen CA125].
Maeda H; Imai S; Morimoto J; Kiyozuka Y; Noda T; Haga S; Hiroishi S
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):320-6. PubMed ID: 1694212
[TBL] [Abstract][Full Text] [Related]
16. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
17. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
Wagner U; Reinsberg J; Krebs D
Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
Houba PH; Boven E; Erkelens CA; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 1998 Dec; 78(12):1600-6. PubMed ID: 9862570
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells.
Aboud-Pirak E; Lesur B; Rao KS; Baurain R; Trouet A; Schneider YJ
Biochem Pharmacol; 1989 Feb; 38(4):641-8. PubMed ID: 2917019
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125.
Kobayashi H; Tamura M; Satoh T; Terao T
Clin Biochem; 1993 Jun; 26(3):213-9. PubMed ID: 8330391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
